I Don’t Know About You, But I’m Feeling These 22 Biotech Stocks
The market is in a transitional phase as we await earnings.
The market is in a transitional phase as we await earnings.
Biotechnology continues to benefit from rotation, but overall corrective action is gaining steam.
Here is how I’m playing a setup in a new name with upcoming catalysts.
Was Wednesday’s poor market performance a warning of things to come?
Traders are increasing speculative action ahead of the holiday.
I’m heavily weighted in this one sector, while adding to one name on news.
There was a quick bounce in tech stocks, but I don’t trust it to last. Meanwhile, I’m building a July shopping list.
We got that rally last week, but under the surface, there are worrying trends.
Here’s how I’m playing a solid reaction to the Iran deal but no euphoria.